Genasense
Navigation Links
Genasense in Medical News
...a
"complete response". The NDA proposed the use of genasense plus
chemotherapy for patients with relapsed or re...d a complete or partial response when treated with genasense plus
chemotherapy compared with patients treated w...appeal of a prior "non-approvable" decision of the genasense NDA in
December 2006. That communication described...
... the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is ...
... the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is ...
Genta Announces Resignation of Dr. Betsy McCaughey from Board of Directors
...ium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients for a global Phase 3 trial of genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is ...Genasense in Medical Technology
Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
...that is intended to support global registration of genasense for patients with advanced melanoma. The study is ...acy results from Genta's prior randomized trial of genasense combined with dacarbazine (DTIC) in patients ident...acy results from an antecedent randomized trial of genasense combined with dacarbazine (DTIC) in patients who h...FDA Lifts Clinical Hold on Genta's Tesetaxel, a Leading Oral Taxane
... the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is ...Genasense(R) Chemotherapy Program Yields High Response Rate in Patients with Stage 4 Melanoma
...or patients with advanced melanoma. In this study, genasense was used to potentially enhance the clinical activ...od marker that was shown to affect the response to genasense plus chemotherapy in a recent randomized trial.) T...CR+PR+SD) of 64%. Laboratory studies showed that genasense did not alter the expected pharmacokinetics of pac......nodular partial response (CR) with the addition of genasense to the Flu/Cy regimen. (17% vs. 7%; P=0.025). In a...lso significantly longer for patients treated with genasense (median not reached but estimated to exceed 36 mon...own that all major responses (CR+PR) achieved with genasense have now been associated with significantly increa...
... the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is ...
Genta Receives Key Patent Related to Oral Gallium Compound G4544
... the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is ...Specialized Genasense(R) Clinical Trials Featured at AACR Meeting
... Quereshi A, et al. Summary: Describes the PK of genasense in patients with impaired kidney function that may...opulation pharmacokinetics (PK) of dacarbazine and genasense in adult patients with advanced melanoma. Authors:...ezai K, et al. Summary: Describes the PK of both genasense and dacarbazine (the chemotherapy drug given to al...DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
...toring Board (DSMB) for AGENDA, a Phase 3 trial of genasense (oblimersen sodium) Injection, which is the Compan...that is intended to support global registration of genasense for patients with advanced melanoma. The study is ...acy results from Genta's prior randomized trial of genasense combined with dacarbazine (DTIC) in patients ident......al Officer. "Our approach mirrors our strategy for genasense in melanoma in which a smaller Phase 3 trial, expe...nfirmatory data." Proposed Confirmatory Trial of genasense in CLL The proposed protocol, based on results o...re - and they will be randomly assigned to receive genasense or no additional therapy. The trial will seek to c...
... melanoma trial -- Decision on FDA appeal for genasense NDA in CLL expected this quarter "Genta now has ...mpany has an ongoing Phase 1-2 trial that combines genasense with Abraxane(R) (paclitaxel protein-bound particl... appealed a prior "non-approvable" decision on the genasense New Drug Application (NDA) for patients with relap...
Genasense in Biological Technology
Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
Submission Based on Increased 5-Year Survival Data for Responding Patients BERKELEY HEIGHTS, N.J., June 6 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced that the Company has submitted an amendment to the Food and Drug Administration (FDA) for its New Drug Appl......that is intended to support global registration of genasense for patients with advanced melanoma. The study is ...acy results from Genta's prior randomized trial of genasense combined with dacarbazine (DTIC) in patients ident...eb/announcements/a030-01.asp . About Genasense genasense inhibits production of Bcl-2, a protein made by ca...
Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights
... CLL submitted to FDA -- AGENDA Phase 3 trial of genasense in melanoma updated at EADO -- Clinical hold on ...e Leading Antisense Drug in Clinical Development genasense in Melanoma: Genta is currently enrolling patients with advanced melanoma in a Phase 3 trial of genasense plus chemotherapy, known as AGENDA. AGENDA is a ra...Genta Announces Second Quarter 2008 Financial Results and Conference Call
... the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is ......nts to the AGENDA Trial, a global Phase 3 trial of genasense in patients with advanced melanoma. The Company ha... Administration requesting approval for the use of genasense plus chemotherapy in patients with relapsed or ref...drug class as paclitaxel and docetaxel. Ganite and genasense are available on a "named-patient" basis in countr...
Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
...o fully enroll the ongoing Phase 3 AGENDA trial of genasense in melanoma, to pursue regulatory actions related to the use of genasense in chronic lymphocytic leukemia, and to make subst...nts to the AGENDA Trial, a global Phase 3 trial of genasense in patients with advanced melanoma. The leading dr...Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights
... product -- FDA provides regulatory guidance for genasense in CLL -- Company restructures to conserve cash ...he Leading Antisense Drug in Clinical Development genasense in Melanoma: Genta is currently enrolling patients...advanced melanoma in a randomized Phase 3 trial of genasense plus chemotherapy, known as AGENDA. The study is d...Genta Announces Transfer of its Common Stock to the OTC Bulletin Board
... the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is ...Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
... the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is ...Genta Restructures Operations to Focus on Priority Initiatives
...ER, this decision precludes a commercial launch of genasense during 2008, and accordingly the Company has reduc...ll be maintaining our "named-patient" programs for genasense and Ganite. However, given the delays in commercia..., and we anticipate clinical presentations on both genasense and G4544 -- an oral compound that reduces calcium...Other TagsMcPhersonSnareMicrosurgicalDavisOther Contentsileushemolytichemolytichemolyticimmunizationsimmunizationsimmunizationsimmunofluorescenceimmunofluorescenceimmunofluorescenceimmunofluorescenceimmunoglobulinimmunoglobulinimmunoglobulinimmunoglobulinimmunoglobulinimmunoglobulinimmunoglobulinimpactedimpactedimpactedimpactedimpacted
(Date:12/15/2009)... Palo Alto Networks(TM), the network security company, today ... Series next-generation firewalls for accurate threat prevention on ... control over applications such as peer-to-peer file sharing. ... with eight facilities on five campuses. The university ... of academic schools and institutions throughout Japan. It ...
(Date:12/15/2009)... fell in area where all couples of reproductive age ... (HealthDay News) -- The number of children born with ... might be CF mutation carriers increases, a new study ... an area of northeast Italy for many years. Since ... decline in the number of infants born with CF. ...
(Date:12/15/2009)... tests promised but not delivered ,, WASHINGTON, ... on Congress to ensure that healthcare reform does ... required of insurance companies in 37 states. ,, ... segments of the population and individuals who are ... and men who have a family history of ...
(Date:12/15/2009)... WASHINGTON, Dec. 15 ... Republican Women Members of Congress that, "it doesn,t matter ... House bills - without a public option - give ... The bills also fund a new social agenda by ... inner city groups, newly arriving immigrants, and local politicians." ...
(Date:12/15/2009)... Physical activity is known to reduce depression and fatigue ... indicates that this effect stems from an individual,s sense ... her ability to achieve certain physical goals. , ... . , "We base our arguments on fatigue being ... of kinesiology and community health at the University of ...
Breaking Medicine News(10 mins):Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Wider Adult Screening May Mean Fewer Children With Cystic Fibrosis 2Health News:Men's Health Network Calls on Congress to Complete President Obama's Promise on Health Care Reform 2Health News:Mastery of physical goals lessens disease-related depression and fatigue 2[0] Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University[0] Wider Adult Screening May Mean Fewer Children With Cystic Fibrosis [1] Men's Health Network Calls on Congress to Complete President Obama's Promise on Health Care Reform[1] Hear the Truth about the Health Bills[0] Mastery of physical goals lessens disease-related depression and fatigue
(Date:12/15/2009)... Economics, environmental impacts, social dynamics, and production ... overall success of an agroecosystem. Positive or negative, ... individuals and social groups to continuously adapt farming ... , Experiential learning theory suggests that knowledge is ... Such lessons are especially valuable for environmental and ...
(Date:12/15/2009)... This release is available in German ... laws everywhere across the globe, cultures vary as to ... example, do not use egocentric terms such as ,left, ... using allocentric notions like ,north, south, east, west, at ... of the bowl" or "There is an snake by ...
(Date:12/15/2009)... Rip currents exact an enormous emotional and economic toll on ... drown in rip currents each year in U.S. waters and ... thousand deaths worldwide. A serious disconnect exists between rip ... confused with rip tides and undertows, and more importantly, most ... escape, from a rip current. , The goal of the ...
Breaking Biology News(10 mins):Experiential learning teaches change and adaptation 2More than a jump to the left 2Pitt research suggests EPA pesticide exposure test too short overlooks long term effects 9604 1Pitt research suggests EPA pesticide exposure test too short overlooks long term effects 9604 2Pitt research suggests EPA pesticide exposure test too short overlooks long term effects 9604 3Pitt research suggests EPA pesticide exposure test too short overlooks long term effects 9604 4Researcher says microchannels could advance tissue engineering methods 9601 1Researcher says microchannels could advance tissue engineering methods 9601 2Researcher says microchannels could advance tissue engineering methods 9601 3Researcher says microchannels could advance tissue engineering methods 9601 4St Josephs Healthcare System Implements 24250 Million Five Year Facilities Project at Paterson and Wayne Campuses 54658 1St Josephs Healthcare System Implements 24250 Million Five Year Facilities Project at Paterson and Wayne Campuses 54658 2St Josephs Healthcare System Implements 24250 Million Five Year Facilities Project at Paterson and Wayne Campuses 54658 3St Josephs Healthcare System Implements 24250 Million Five Year Facilities Project at Paterson and Wayne Campuses 54658 4St Josephs Healthcare System Implements 24250 Million Five Year Facilities Project at Paterson and Wayne Campuses 54658 5| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |